TY - JOUR

T1 - Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider

T2 - Part 2: at the emergency department

AU - Milicic, Davor

AU - Ben Avraham, Binyamin

AU - Chioncel, Ovidiu

AU - Barac, Yaron D.

AU - Goncalvesova, Eva

AU - Grupper, Avishai

AU - Altenberger, Johann

AU - Frigeiro, Maria

AU - Ristic, Arsen

AU - De Jonge, Nicolaas

AU - Tsui, Steven

AU - Lavee, Jacob

AU - Rosano, Giuseppe

AU - Crespo-Leiro, Marisa Generosa

AU - Coats, Andrew J. S.

AU - Seferovic, Petar

AU - Ruschitzka, Frank

AU - Metra, Marco

AU - Anker, Stefan

AU - Filippatos, Gerasimos

AU - Adamopoulos, Stamatis

AU - Abuhazira, Miriam

AU - Elliston, Jeremy

AU - Gotsman, Israel

AU - Hamdan, Righab

AU - Hammer, Yoav

AU - Hasin, Tal

AU - Hill, Lorrena

AU - Itzhaki Ben Zadok, Osnat

AU - Mullens, Wilfried

AU - Nalbantgil, Sanemn

AU - Piepoli, Massimo Francesco

AU - Ponikowski, Piotr

AU - Potena, Luciano

AU - Ruhparwar, Arjang

AU - Shaul, Aviv

AU - Tops, Laurens F.

AU - Winnik, Stephan

AU - Jaarsma, Tiny

AU - Gustafsson, Finn

AU - Ben Gal, Tuvia

N1 - Publisher Copyright: © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

PY - 2021

Y1 - 2021

N2 - The improvement in left ventricular assist device (LVAD) technology and scarcity of donor hearts have increased dramatically the population of the LVAD-supported patients and the probability of those patients to present to the emergency department with expected and non-expected device-related and patient–device interaction complications. The ageing of the LVAD-supported patients, mainly those supported with the ‘destination therapy’ indication, increases the risk for those patients to suffer from other co-morbidities common in the older population. In this second part of the trilogy on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider, definitions and structured approach to the LVAD-supported patient presenting to the emergency department with bleeding, neurological event, pump thrombosis, chest pain, syncope, and other events are presented. The very challenging issue of declaring death in an LVAD-supported patient, as the circulation is artificially preserved by the device despite no other signs of life, is also discussed in detail.

AB - The improvement in left ventricular assist device (LVAD) technology and scarcity of donor hearts have increased dramatically the population of the LVAD-supported patients and the probability of those patients to present to the emergency department with expected and non-expected device-related and patient–device interaction complications. The ageing of the LVAD-supported patients, mainly those supported with the ‘destination therapy’ indication, increases the risk for those patients to suffer from other co-morbidities common in the older population. In this second part of the trilogy on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider, definitions and structured approach to the LVAD-supported patient presenting to the emergency department with bleeding, neurological event, pump thrombosis, chest pain, syncope, and other events are presented. The very challenging issue of declaring death in an LVAD-supported patient, as the circulation is artificially preserved by the device despite no other signs of life, is also discussed in detail.

U2 - 10.1002/ehf2.13587

DO - 10.1002/ehf2.13587

M3 - Journal article

C2 - 34523254

AN - SCOPUS:85115100355

VL - 8

SP - 4409

EP - 4424

JO - E S C Heart Failure

JF - E S C Heart Failure

SN - 2055-5822

IS - 6

ER -